Announcements Trials
Browse Landscape

Phase

Phase 2 14Phase 3 6Phase 1 3Phase NA 1Phase 4 1Phase 2/3 1Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Breast Neoplasms 16Carcinoma, Non-Small-Cell Lung 5Lung Neoplasms 2Head and Neck Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms 1Neoplasms, Second Primary 1NSCLC 1Locally Advanced Breast Cancer 1Carcinoma, Squamous Cell 1Adenocarcinoma 1

Interventions

ferric carboxymaltose 2Pemetrexed 2Drug Therapy 2iron isomaltoside 1000 1icotinib 1ferrous sulfate 1elemene 1aumolertinib 1aflutinib 1Rabeprazole 1Gemcitabine 1Docetaxel 1Desflurane 1Carboplatin 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Adenocarcinoma × Docetaxel × Clear all
NCT01665417 2017-02-08

Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma

Betta Pharmaceuticals Co., Ltd.

Phase 4 Unknown
100 enrolled
Tumor-Agnostic

Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡